Digital Technologies Transforming Bioprocessing
Watch Dr. Michael Sokolov, COO of DataHow, explain what hybrid models are and how they are impacting process development and manufacturing, and how, with the right application, hybrid bioprocess models have far-reaching impacts from the lab to general business performance.
Speakers
-
Dr. Michael Sokolov
Founder & COO DataHow AG
Overview
Dr. Michael Sokolov, COO of DataHow, explained what hybrid models are and how they are impacting process development and manufacturing with their AI and machine learning core and their ability to generate richer insights faster. He explained how, with the right application, hybrid bioprocess models have far-reaching impacts from the lab to general business performance.
With this technology, new standards are being set in bioprocess development. Their ability to decipher insight from process data during development outperforms traditional methods and has far reaching impacts on how the biopharmaceutical industry approaches process development and the results which can be acheived.
This webinar allows process development and manufacturing management to understand this emerging technology and its potential impact on their organization.
In this webinar, key topics included:
What is a hybrid model?
Why are they important in the lab, and for the business?
The impact: a case study review;
Are they applicable to your operation?
Key management outtakes.